Progression of Multiple Myeloma or Plasma Cell Leukemia
specificProgression of multiple myeloma or plasma cell leukemia requires any one or more of the following: Increase of 25% or more from baseline in: serum M-component with an absolute increase 0.5 g/dL or more (for progressive disease, serum M-component increases of 1 g/dL or more are sufficient to define relapse if the starting M component is 5 g/dL or more); urine M-component with an absolute increase 200 mg. or more/ 24 hours; for recipients without measurable serum and urine M-protein levels: the di
7
Centers
0
Active Trials
—
Cancer Funding
Top Centers for Progression of Multiple Myeloma or Plasma Cell Leukemia(7)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Fred Hutch Cancer CenterSeattle, WA NCI Comprehensive | 57.1 |
| 2 | Stanford Cancer InstitutePalo Alto, CA NCI Comprehensive | 57.1 |
| 3 | Winship Cancer InstituteAtlanta, GA NCI Comprehensive | 57.1 |
| 4 | OHSU Knight Cancer InstitutePortland, OR NCI Comprehensive | 57.1 |
| 5 | Huntsman Cancer Institute at the University of UtahSalt Lake City, UT NCI Comprehensive | 57.1 |
| 6 | The University of Arizona Cancer CenterTucson, AZ NCI Comprehensive | 57.1 |
| 7 | Medical College of Wisconsin Cancer CenterMilwaukee, WI | 57.1 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →